CytoMed Therapeutics (GDTC) to form cord blood NK cell biotech unit

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that it has successfully expanded clinical-scale natural killer (NK) cells from cord blood units, adding to its existing adult peripheral blood mononuclear cell-derived therapeutics. The company intends to reorganize and streamline its group structure to create a new cord blood-derived biotech business. According to the referenced press release, this move supports an expansion into auto-immune diseases and builds on a recent cord blood bank acquisition.

Insights

Biotech strategy analyst

CytoMed is pivoting part of its platform toward cord blood NK cell therapies and auto-immune indications.

CytoMed Therapeutics states it has achieved clinical-scale expansion of natural killer (NK) cells from cord blood units, alongside its adult blood cell-derived therapeutics. Reaching clinical scale for cord blood NK cells suggests the company is preparing for use in human studies or partnerships centered on this cell source.

The company also plans to reorganize and streamline its group structure to create a dedicated cord blood-derived biotech business. This structural change, tied to a recent cord blood bank acquisition and an expansion into auto-immune diseases, indicates a clearer focus on this platform. The actual financial impact will depend on future development steps, which are not detailed here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Registrant’s Name)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release, announcing that in addition to adult peripheral blood mononuclear cell-derived therapeutics, the Company has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units, and intends to re-organize and streamline its group structure to create a new cord blood-derived biotech.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Financial Statements and Exhibits.

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press Release dated August 28, 2025, titled “CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
Date: August 28, 2025	By:	/s/ Choo Chee Kong
	Name:	Choo Chee Kong
	Title:	Chairman and Director

2

FAQ

What did CytoMed Therapeutics (GDTC) report in this Form 6-K?

CytoMed Therapeutics reported that it has successfully expanded clinical-scale natural killer (NK) cells from cord blood units and plans to reorganize its group structure to create a new cord blood-derived biotech business.

How is CytoMed Therapeutics expanding its cell therapy work?

The company states it has added clinical-scale NK cells from cord blood units to its existing adult peripheral blood mononuclear cell-derived therapeutics, broadening its cell therapy platforms.

What structural changes does CytoMed Therapeutics intend to make?

CytoMed Therapeutics intends to reorganize and streamline its group structure in order to create a new cord blood-derived biotech entity within its business.

Which disease areas is CytoMed Therapeutics targeting with this move?

According to the referenced press release title, CytoMed Therapeutics is expanding into auto-immune diseases, building on its recent cord blood bank acquisition.

What exhibit was included with CytoMed Therapeutics’ Form 6-K?

The filing includes Exhibit 99.1, a press release dated August 28, 2025, titled “CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition.”

Does the Form 6-K mention a new cord blood-focused business for CytoMed Therapeutics?

Yes. CytoMed Therapeutics indicates it intends to create a new cord blood-derived biotech by reorganizing and streamlining its existing group structure.